In a nutshell This study determined the effects of liraglutide (Victoza) on blood pressure (BP) and heart rate in patients with hypertension (abnormally high blood pressure) and poorly controlled Type 2 diabetes (T2D). This study concluded that liraglutide improved systolic BP (SBP; the first number of the BP which refers to the pressure when the heart...
Read MoreIn a nutshell This phase 3 clinical trial is investigating the effects of sotagliflozin on cardiovascular disease and kidney disease, in people with type 2 diabetes (T2D). The main outcome to be tested is the time until a major adverse cardiovascular event (MACE) or heart failure occurs. The details Two proteins, called SGLT1 and SGLT2, are important...
Read MoreIn a nutshell This trial is examining the effects of different diabetes self-management strategies in African American and Hispanic women with type 2 diabetes (T2D). The main outcomes to be measured will be the change in physical activity levels and the change in HbA1c (measures average blood glucose over the last 3 months). This study is being conducted...
Read MoreIn a nutshell This phase 3 clinical trial is investigating the safety and effectiveness of dapagliflozin (Forxiga) and saxagliptin (Onglyza) in young people with type 2 diabetes (T2D). The main outcome to be measured will be change in HbA1c (measures average blood glucose over the last 3 months) after 6 months of treatment. The details Dapagliflozin...
Read More
In a nutshell This study evaluated the safety of a combination of empagliflozin (Jardiance) and linagliptin (Tradjenta) compared to either drug on its own, in people with type 2 diabetes (T2D). It was determined that the combination was as safe as either drug alone. Some background Metformin (Glucophage) is usually the first drug given to...
Read More
In a nutshell This study compared the safety and effectiveness of empagliflozin (Jardiance) with glimepiride (Amaryl) in people with type 2 diabetes (T2D). It was determined that empagliflozin reduced HbA1c more than glimepiride, and had a lower overall risk of side effects. Some background Metformin (Glucophage) is usually the first drug given...
Read More
In a nutshell This study investigated the safety and effectiveness of semaglutide (Ozempic) in people with type 2 diabetes (T2D). It was determined that semaglutide lowers HbA1c (measures average blood glucose over the last 3 months) without significantly increasing weight gain, hypoglycemia, or gastrointestinal (GI) side effects. Some background...
Read More
In a nutshell This study compared the safety of using three different medications to treat type 2 diabetes (T2D) with using only two of those medications. It was determined that using three medications was as safe as using two. Some background Control of blood glucose levels is important to prevent the long-term complications of T2D....
Read More
In a nutshell This study investigated the effectiveness and safety of adding SGLT2 inhibitors to insulin in type 1 diabetes (T1D). The authors concluded that add-on SGLT-2 inhibitor therapy may be helpful for T1D, but should be carefully considered due to potential side effects. Some background The goal of T1D management is to reach and maintain...
Read More
In a nutshell This study investigated the long-term glycemic (blood sugar) control of type 2 diabetes patients receiving second-line medications with or without metformin (Glucophage). This study concluded that GLP-1 receptor agonists, DPP-4 inhibitors and thiazolidinedione-based therapies offer a higher chance of long-term glycemic control compared to...
Read More
In a nutshell This study determined the safety and effectiveness of ertugliflozin (Steglatro) as a single therapy for adults with poorly controlled type 2 diabetes despite diet and exercise. This study concluded that 1 year of ertugliflozin improved glycemic (blood sugar) control and reduced body weight and blood pressure, but increased genital...
Read More
In a nutshell This study assessed the ability of two types of insulin therapy in preventing possible side effects of type 1 diabetes (T1D) in young patients. The authors concluded that insulin pump therapy was better than injection therapy at preventing hypoglycemia and diabetic ketoacidosis...
Read More
